“PHARMA GREED KILLS.” “PEOPLE OVER PROFIT” “Heather Bresch: THE FACE OF GREED” So resounds the public outrage toward Mylan Inc. and the company’s CEO Heather Bresch after having steadily increased the price of EpiPen from $100 in 2007 to $600 last May.1 Critics argue that the price to manufacture the injector has not increased during that time, that the product itself has not changed, that research and development costs cannot justify the decision, and that